Studien der German Lymphoma Alliance
Akademische Studien der GLA
Alternative C - GLA 2020-2ARCHED - GLA 2022-1ASTRAL - GLA 2019-5CARMAN - GLA 2022-11Charly - GLA 2017-4COPA-R-CHOP - GLA 2020-1COUP-1 - GLA 2019-3CZAR-1 - GLA 2021-2DETECT_CNSL - GLA 2022-9ECWM-1 - GLA 2014-1ECWM-2 - GLA 2019-2FORTplus - GLA 2022-5GAZAI - GLA 2018-3GDL-ISRT 20 Gy - GLA 2019-4GOAL-II - GLA 2021-1ImbruVeRCHOP-Trial - GLA 2017-2KILT trialMARTA - GLA 2017-1MATRix - IELSG43 - GLA 2014-3MCL Elderly III - GLA 2022-3MCL R2 elderly - GLA 2015-2MMML Predict - GLA 2022-8MTR² - GLA 2022-7Niveau - GLA 2018-1OLYMP-1 - GLA 2019-1OPTIMAL - GLA 2011-1OptiMATe - GLA 2021-4Pola-R-ICE - GLA 2021-3POLE-1 - GLA 2022-4PRIMA-CNS - GLA 2022-2PTLD 2 - GLA 2015-1R-CHOEP brut - GLA 2018-2R-Pola-Glo - GLA 2022-10ReBeL - GLA 2014-2TRIANGLE - GLA 2016-1VALIDATE - GLA 2021-5VenObi - GLA 2020-3VIWA-1 - GLA 2022-6